For instance, a phase II clinical study found pembrolizumab ineffective in TKI-naïve patients with advanced NSCLC and high PD-L1 expression (≥ 50%) in the EGFR-mutant setting [50]. Here, EGFR is linked to non-small cell lung carcinoma.